Date: 2012-10-10
Type of information: Production agreement
Compound: induced pluripotent stem cells (iPSCs)
Company: Lonza (Switzerland), NIH Center for Regenerative Medicine (NIH CRM) (USA)
Therapeutic area:
Type agreement: manufacturing
production
Action mechanism:
Disease:
Details: The National Institutes of Health Center for Regenerative Medicine (NIH CRM) has awarded Lonza Walkersville, Inc. a contract to generate induced pluripotent stem cells (iPSCs) under current Good Manufacturing Practices (cGMP). The contract also includes manufacturing of clinical grade iPSC-derived cell types. Lonza has recently entered a worldwide, non-exclusive licensing agreement with iPS Academia Japan, Inc. for its induced pluripotent stem cell (iPSC) patent portfolio. By gaining rights to these patents, Lonza is adding to its market leading portfolio of cell therapy services and products that include process development and assay development as well as manufacturing therapeutic cells under current Good Manufacturing Practices (cGMP).
Financial terms: The Lonza contract is a five year agreement with a value of approximately $9.5 million. The contract awarded to Lonza is deemed an Indefinite Delivery/Indefinite Quantity (IDIQ) award which is a type of United States Government contract that provides an indefinite quantity of services for a fixed amount time. For IDIQs, although nothing is guaranteed, minimum and maximum quantity limits are specified in the basic contract as either number of units (for supplies) or as dollar values (for services).
Latest news:
